ARTham Therapeutics Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ARTham Therapeutics Inc - overview
Established
2018
Location
Yokohama, -, Japan
Primary Industry
Pharmaceuticals
About
ARTham Therapeutics Inc is a biotech firm focused on developing innovative therapeutic solutions for a range of medical conditions, leveraging cutting-edge technologies to address unmet clinical needs. Founded in 2018 and headquartered in Yokohama, Japan, ARTham Therapeutics Inc specializes in the biopharmaceutical sector. The company underwent a change in ownership when it was acquired by Kaken Pharmaceutical Co. , Ltd.
in December 2021, transitioning from a previous investment structure involving several venture capital firms. The founder's specific history isn't detailed, nor are any previous companies mentioned. The company has successfully completed three funding deals, culminating in a TRADE SALE round that raised JPY 5,500. 00 mn, entirely accounted for in the total amount raised.
ARTham Therapeutics Inc specializes in developing innovative therapeutic solutions aimed at addressing various medical conditions. The company focuses on the application of advanced biopharmaceutical technologies to enhance treatment options for patients, with an emphasis on meeting clinical needs through research and development. ARTham Therapeutics Inc generates revenue through the commercialization of its therapeutic products, based on a pricing model that considers the development and operational costs associated with bringing new therapies to market. The company's revenue strategy is aligned with fostering partnerships in the healthcare sector, ensuring ongoing support and updates to its product offerings.
Looking ahead, ARTham Therapeutics Inc is positioned to expand its product portfolio with new therapeutic solutions currently under development, focusing on addressing critical health challenges. The company aims to penetrate new geographical markets, targeting expansions in North America and Europe by the end of 2025. The recent acquisition by Kaken Pharmaceutical Co. , Ltd.
will facilitate these initiatives, leveraging the financial backing and expertise required to support product development and market entry strategies.
Current Investors
SMBC Venture Capital, Mizuho Capital, Yokohama Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.arthamther.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.